Mechanical versus biological prostheses for surgical aortic valve replacement in patients aged 50-70.
Usage of biological prosthesis is increasing in surgical aortic valve replacement (SAVR). Recent U.S. guidelines recommend either biological or mechanical prosthesis for SAVR in patients aged 50-70 years. We set out to study long-term outcomes of mechanical vs. biological prosthetic valves in this patient group. All patients (excluding infective endocarditis and other concomitant surgery than CABG) aged 50-70 with first-time SAVR in Finland between 2004-2014 were retrospectively studied (n=2928). Propensity score matching (1:1) was used to identify patients with comparable baseline features (n=1152). Outcomes were 10-year all-cause mortality, aortic valve re-operation, major bleeding, ischemic stroke, and infective endocarditis. Mean follow-up was 6.7 years. Ten-year all-cause mortality was 18.6% with mechanical and 27.6% with biological valve (HR 0.72; CI 0.54-0.97, p=0.028). Prosthetic valve re-operation was performed in 1.4% with mechanical and in 8.5% with bioprosthetic valves (HR 0.30; CI 0.12-0.74; p=0.009). Major bleeding occurred to 21.5% with mechanical and to 16.9% with biological prostheses (HR 1.19; p=0.402). Rates of intracranial bleeding were also comparable. Ischemic stroke rates within 10-years were 12.7% with mechanical and 9.3% with biological valves (HR 1.29; p=0.316). Infective endocarditis occurred in 3.7% of mechanical and in 7.3% of biological valves (HR 0.46; CI 0.24-0.88; p= 0.018). Mechanical valve prostheses were associated with lower mortality, lower rates of re-operation, and lower occurrence of infective endocarditis compared to bioprostheses within 10-years after SAVR in matched patients aged 50-70. Our results do not support the routine use of biological valve prostheses in this patient group.